BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - BioCryst Pharma (NASDAQ:BCRX)

BioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.

BioCryst Pharmaceuticals is set to present new real-world evidence at the ISPOR 2026 conference, highlighting the persistent challenges faced by children with hereditary angioedema (HAE). The presentation will underscore the significant burden this condition places on young patients, offering insights into the specific difficulties and impact on their lives. This data aims to shed light on the realities of living with HAE for the pediatric population.

BioCryst Pharmaceuticals secured a European licensing deal for its investigational HAE therapy, navenibart, with an Irish affiliate of Neopharmed Gentili. The agreement includes a US$70 million upfront payment, potential milestones up to US$275 million, and tiered royalties, providing a capital infusion for BioCryst's Phase 3 development. While this deal strengthens short-term funding and leverages an existing European infrastructure, the company's long-term success still hinges on ORLADEYO's performance and navenibart's trial outcomes amidst rising competition in the HAE market.

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 30,700 ...

Image source: The Motley Fool.Monday, Nov. 3, 2025 at 8:30 a.m. ETChief Executive Officer - John StonehouseContinue reading ...

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.